Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Jung KH, et al. Among authors: soliman h. Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15. Clin Cancer Res. 2019. PMID: 30770348 Free PMC article. Clinical Trial.
A phase I study of indoximod in patients with advanced malignancies.
Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. Soliman HH, et al. Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216. Oncotarget. 2016. PMID: 27008709 Free PMC article. Clinical Trial.
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer.
Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ. Wainberg ZA, et al. Among authors: soliman hh. Clin Cancer Res. 2020 Sep 15;26(18):4814-4822. doi: 10.1158/1078-0432.CCR-20-0099. Epub 2020 Jun 18. Clin Cancer Res. 2020. PMID: 32554514 Clinical Trial.
A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.
Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Rosa M, Khong H, Czerniecki B. Soliman H, et al. Clin Cancer Res. 2021 Feb 15;27(4):1012-1018. doi: 10.1158/1078-0432.CCR-20-3105. Epub 2020 Nov 20. Clin Cancer Res. 2021. PMID: 33219014 Clinical Trial.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Emens LA, et al. Among authors: soliman h. J Immunother Cancer. 2021 Aug;9(8):e002597. doi: 10.1136/jitc-2021-002597. J Immunother Cancer. 2021. PMID: 34389617 Free PMC article.
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Tolaney SM, et al. Among authors: soliman h. Clin Cancer Res. 2022 Apr 14;28(8):1500-1506. doi: 10.1158/1078-0432.CCR-21-3276. Clin Cancer Res. 2022. PMID: 35121623 Free PMC article. Clinical Trial.
838 results